[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338910-105":59,"doc-detail-338910-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","upregulation-of-enhancer-of-zeste-homolog-2-ezh2-with-associated-perk-co-expression-and-prc2-complex-protein-suz12-correlation-in-adult-t-cell-leukemialymphoma","Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma","","Adult T-cell leukemia/lymphoma (ATLL) is highly aggressive and resistant to standard therapies, creating a need for new targets. This study examines EZH2, an epigenetic regulator, and evaluates its correlation with signaling and PRC2 complex components in ATLL. Immunohistochemistry quantified EZH2, pERK, MYC, and pSTAT3 in 43 ATLL cases and 104 other T-cell neoplasms, with additional analysis of Ki-67, SUZ12, and H3K27me3 in ATLL. Results show EZH2 overexpression in all ATLL cases and frequent EZH2 overexpression in other T-cell neoplasms, with ATLL EZH2 linked to pERK co-expression, increased proliferation, and SUZ12/H3K27me3 co-expression, suggesting a PRC2-dependent catalytic mechanism and supporting EZH2 and pERK as therapeutic targets.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/upregulation-of-enhancer-of-zeste-homolog-2-ezh2-with-associated-perk-co-expression-and-prc2-complex-protein-suz12-correlation-in-adult-t-cell-leukemialymphoma/338910/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/upregulation-of-enhancer-of-zeste-homolog-2-ezh2-with-associated-perk-co-expression-and-prc2-complex-protein-suz12-correlation-in-adult-t-cell-leukemialymphoma/338910.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main focus of this study in ATLL?","Question",{"text":113,"@type":114},"The study focuses on EZH2 upregulation and how it correlates with pERK co-expression and components of the PRC2 complex in adult T-cell leukemia/lymphoma.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was EZH2 and related signaling measured?",{"text":118,"@type":114},"Immunohistochemical staining was performed for EZH2, pERK, MYC, and pSTAT3 across ATLL and other T-cell neoplasm cases, with further IHC for Ki-67, SUZ12, and H3K27me3 in ATLL.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study find about EZH2 overexpression in ATLL and other T-cell neoplasms?",{"text":122,"@type":114},"All ATLL cases showed EZH2 overexpression, and other T-cell neoplasms also exhibited a high prevalence of EZH2 overexpression (86%), except T-PLL (33%).",{"name":124,"@type":111,"acceptedAnswer":125},"Why do the authors suggest EZH2 and pERK could be therapeutic targets?",{"text":126,"@type":114},"EZH2 overexpression in ATLL correlated with pERK expression, higher proliferation index (Ki-67), and PRC2 activity markers (SUZ12 and H3K27me3), indicating a link to tumor aggressiveness and supporting EZH2 and pERK as potential targets.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},338910,1790359937,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","cancers   \nArticle  \nUpregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma  \nJiani Chai 1, Jui Choudhuri 1, Jerald Z. Gong 2, Yanhua Wang 1 and Xuejun Tian 2, *  \nCitation: Chai, J.; Choudhuri, J.; Gong, J.Z.; Wang, Y.; Tian, X. Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma. Cancers 2024, 16, 646. [https://](https://)  \n[doi.org/10.3390/cancers16030646](doi.org/10.3390/cancers16030646)[ ](doi.org/10.3390/cancers16030646)Academic Editor: Ferenc Gallyas, Jr.  \nReceived: 4 January 2024  \nRevised: 23 January 2024  \nAccepted: 29 January 2024  \nPublished: 2 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Montefiore Medical Center, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10467, USA; [ywang@montefiore.org](ywang@montefiore.org) (Y.W.)  \n2 Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA; [jerald.gong@jefferson.edu](jerald.gong@jefferson.edu)  \n* Correspondence: [xuejun.tian@jefferson.edu](xuejun.tian@jefferson.edu); Tel.: +1-(215)-955-0778; Fax: +1-(215)-955-2604  \nSimple Summary: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive mature T-cell neoplasm with an extremely poor prognosis. For decades, the first-line therapy for ATLL has been CHO(E)P, although treatment refractoriness and relapse are common. Therefore, there is a need to search for new treatment options. This study, focusing on EZH2, an important epigenetic regulator, and associated intracellular signaling molecules, demonstrates that both EZH2 and pERK expression are upregulated in ATLL, contributing to tumor aggressiveness in biopsied patients’ tumor tissues. Their inhibitors could be potential therapeutic targets for these aggressive T-cell neoplasms.  \nAbstract: EZH2, a subunit of the polycomb repressive complex 2 (PRC2), is an important methyltransferase that catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3) . EZH2 is overexpressed in various malignancies. Here, we investigated EZH2 expression and potential signaling molecules that correlate with EZH2 expression in ATLL and other T-cell neoplasms. Immunohistochemical staining (IHC) was performed for EZH2, pERK, MYC, and pSTAT3 on 43 ATLL cases and 104 cases of other T-cell neoplasms. Further IHC studies were conducted for Ki-67, SUZ12, and H3K27me3 on ATLL cases. All ATLL cases showed EZH2 overexpression. In other T-cell neoplasms, a high prevalence of EZH2 overexpression was identified (86%), except for T-PLL (33%) . In ATLL, EZH2 overexpression correlated with pERK co-expression (86%), while only a small subset of cases showed MYC (7%) or pSTAT3 (14%) co-expression. In the other T-cell neoplasms, there was a variable, but higher, co-expression of EZH2 with pERK, MYC, and pSTAT3 . In ATLL, enhanced EZH2 expression correlated with higher Ki-67 staining, SUZ12 (another PRC2 subunit), and H3K27me3 co-expression. In conclusion, EZH2 is overexpressed in ATLL and is associated with pERK expression. It correlates with an increased proliferation index, indicating an aggressive clinical course. EZH2 also correlates with SUZ12 and H3K27me3 co-expression, suggesting its PRC2-dependent catalytic activity through trimethylation. Additionally, EZH2 is overexpressed in most T-cell neoplasms, suggesting that EZH2 could function as an oncogenic protein in T-cell tumorigenesis. EZH2 and pERK could serve as potential therapeutic targets for treating aggressive ATLL. EZ","cbCaioDJFwB6OIaq","https://ap.wps.com/l/cbCaioDJFwB6OIaq","pdf",6683450,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is the main focus of this study in ATLL?\",\"answer\":\"The study focuses on EZH2 upregulation and how it correlates with pERK co-expression and components of the PRC2 complex in adult T-cell leukemia/lymphoma.\"},{\"question\":\"How was EZH2 and related signaling measured?\",\"answer\":\"Immunohistochemical staining was performed for EZH2, pERK, MYC, and pSTAT3 across ATLL and other T-cell neoplasm cases, with further IHC for Ki-67, SUZ12, and H3K27me3 in ATLL.\"},{\"question\":\"What did the study find about EZH2 overexpression in ATLL and other T-cell neoplasms?\",\"answer\":\"All ATLL cases showed EZH2 overexpression, and other T-cell neoplasms also exhibited a high prevalence of EZH2 overexpression (86%), except T-PLL (33%).\"},{\"question\":\"Why do the authors suggest EZH2 and pERK could be therapeutic targets?\",\"answer\":\"EZH2 overexpression in ATLL correlated with pERK expression, higher proliferation index (Ki-67), and PRC2 activity markers (SUZ12 and H3K27me3), indicating a link to tumor aggressiveness and supporting EZH2 and pERK as potential targets.\"}]","Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma | PDF",1790026488,25,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a369e03c29b6b0531ef36450ffa1803f.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4168bf84fae16b69bc5da19b106f19ae.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6dbc68e9be4847175b556ee826d3188.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dbe25bcdacc39b05c2c8a420035cadc.webp",980,1385]